B cells and B cell directed therapies in CNS inflammation

B08

B cells are an important therapeutic target in MS. While anti-CD20 therapy (depleting B cells) is beneficial in MS, targeting the B cell survival factors B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with atacicept worsened MS. The reasons for this apparent paradox are unclear, but indicate that the BAFF-APRIL system influences MS in a way that has not yet been understood. We aim to investigate the molecular and cellular basis of mechanism of action of different B cell directed therapies that are currently in use or being developed. In detail, we intend to analyze effects of different B cell directed therapies in peripheral and intrathecal compartments both in MS patients and in B cell dependent animal models including a spontaneous disease model featuring formation of autoantibodies and a Th17 adoptive transfer model featuring formation of submeningeal ectopic lymphoid follicles. These questions will guide our research::

    1. Why did blocking of BAFF and APRIL by atacicept worsen MS?
    2. What are the mechanistic details of anti-CD20 therapy?
    3. Inhibition of Bruton’s Tyrosine Kinase (BTK) is a promising novel therapeutic strategy in MS. How does the inhibition of BTK influence neuroinflammation?

 

 

 

 

 

 

 

 

 

 

 

Laurent et al., Nat Commun., 2015

 

Principal Investigators:

Prof. Dr. med. Edgar Meinl
Institut für klinische Neuroimmunologie
LMU München
edgar.meinl@med.uni-muenchen.de

Dr. rer nat. Anneli Peters
Institut für klinische Neuroimmunologie
LMU München
anneli.peters@med.uni-muenchen.de

News

Thu, 15/09/2022
Photo gallery: Inflammation & Imaging Symposium in the MIC building
Muenster. From September 12th to 14th scientists from Muenster University and their international guests discussed the latest developments in research on inflammation and the imaging of the immune system at the 2nd Inflammation & Imaging Symposium. The annual event is jointly organised by several research networks from Münster, among them the CRC/TRR 128 “Multiple Sclerosis”. […]...more
Tue, 28/06/2022
CRC Retreat in Münster
Muenster. After a long pause, more than 90 participants of the CRC joined in Muenster Factory Hotel to update on the latest developments. We heard the most recent on a selection of the CRC projects and there was also plenty of time for fruitful discussion and socializing in the evening....more
Mon, 23/05/2022
EU Research Council awards Lydia Sorokin Advanced Grant
Münster – The biochemist and Principal investigator of the CRC 128 Prof. Dr. Lydia Sorokin has received the coveted “Advanced Grant” awarded by the European Research Council (ERC). The funding of ca. 2.3 million euros enables the realisation of outstanding research projects. Lydia Sorokin heads the Institute for Physiological Chemistry and Pathobiochemistry at Muenster University. […]...more